Patents by Inventor William WIRE

William WIRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
    Publication number: 20240002374
    Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: May 11, 2022
    Publication date: January 4, 2024
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Sylvie Baltzer, Bertrand Vivet, Brian Freed, Hans Peter Nestler, Helen Yeoman, Ingrid Mechin, Martin Smrcina, Nina Ma, Sylvain Lebreton, Ryan Hartung, William Wire, Sukanthini Thurairatnam
  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230159438
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 25, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Helen Yeoman, Martin Smrcina, Ronghua Li, Ryan Hartung, William Wire, Bertrand Vivet, Nina Ma
  • SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
    Publication number: 20100113462
    Abstract: The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
    Type: Application
    Filed: November 30, 2009
    Publication date: May 6, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Thomas J. CAULFIELD, Jennifer Williford CLEMENS, Robert S. FRANCIS, Brian S. FREED, Stanly JOHN, Tieu-Binh LE, Brian PEDGRIFT, Antonio D. RAMOS, Gerard Charles ROSSE, Martin SMRCINA, David S. THORPE, William WIRE, Jianhong ZHAO